chartexchange

GNCAQ
GENOCEA BIOSCIENCES INC
stockOTC

EODNov 16, 2026
0.00001USD+900.000%(+0.00001)804
Loading…
Loading…
Healthcare
Biotechnology
HQ
Cambridge, MA, USA
Previous Close
$0.00
Beta
26.68
52-Week High
$0.01 2026-05-19
52-Week Low
$0.00 2026-10-22
SMA 50
$0.00
SMA 200
$0.00
Avg. Vol 10D
5,973
Avg. Vol 30D
4,591
Avg. Vol 90D
4,742
Relative Vol
0.18
GNCAQ Profile

genocea is harnessing the power of t cell immunity to develop life-changing vaccines and immunotherapies. while traditional immunotherapy discovery methods have largely used predictive methods to propose t cell targets, or antigens, genocea has successfully developed atlas™, its proprietary technology platform, to identify clinically relevant antigens of t cells based on actual human immune responses. genocea is currently using atlas in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by epstein-barr virus.

GNCAQ Performance
PeriodPriceDateChangeBeta
1M0.002026-10-21+900.00%-536.401
3M0.002026-08-20+900.00%-152.997
6M0.002026-05-21+900.00%84.233
1Y0.002025-11-19+900.00%26.679
2Y0.002024-11-21+900.00%—
5Y0.002023-05-12-90.00%84.939
GNCAQ Stock Summary

GENOCEA BIOSCIENCES INC (OTC:GNCAQ) stock price today is $0.00, and today's volume is 804. GNCAQ is up 900.000% today. The 30 day average volume is 4,591. GNCAQ market cap is $588 with 58.78M shares outstanding.